Altogether, these observations support the concept that targeting different steps of the SL pathway (in particular SPHK1 and GCS) may be a beneficial strategy to overcome TKI resistance in CML. Here, SPHK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.